1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women

R. J. Duda, R. Kumar, K. I. Nelson, A. R. Zinsmeister, K. G. Mann, B. L. Riggs

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

The cause of bone loss in postmenopausal osteoporosis - decreased bone formation or increased bone resorption - is controversial. Synthesis of bone-Gla protein (BGP), a specific osteoblast product, is stimulated by 1,25-dihydroxyvitamin D3 [1,25(OH)2D] in vitro. Thus, increases in serum BGP levels during 1,25(OH)2D administration might provide a useful dynamic index of osteoblast function. We compared 14 postmenopausal osteoporotic women with 12 age-matched postmenopausal normal women before and during 6 d of 1,25(OH)2D administration (2.0 μg/d). Serum BGP levels were similar at baseline and increased during treatment in both groups (P < 0.001). However, trend analysis showed a greater (P < 0.01) increase in the osteoporotic women. These data do not support the hypothesis that defective osteoblast function is the major cause of bone loss in postmenopausal osteoporosis.

Original languageEnglish (US)
Pages (from-to)1249-1253
Number of pages5
JournalJournal of Clinical Investigation
Volume79
Issue number4
DOIs
StatePublished - 1987

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of '1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women'. Together they form a unique fingerprint.

Cite this